DPA-714 and FDG PET/MRI in Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-23

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression, a common psychological disorder, is characterized by persistent low mood, loss of interest, and anhedonia, leading to significant dysfunctions and a high suicide risk. Its pathogenesis remains challenging, with recent focus on neuroinflammation-a chronic immune response in the central nervous system-as a potential contributor. PET imaging, using tracers like 18F-FDG and \[18F\]DPA-714, can visualize metabolic and neuroinflammatory changes. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms. We hypothesize that microglial activation in depression, especially in major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions, will show higher TSPO levels and increased glucose metabolism compared to the control group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder

NCT06452290

Major Depressive Disorder

NOT_YET_RECRUITING NA

Brain Inflammation in Major Depressive Disorder Background

NCT01851356

Major Depression

COMPLETED

[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

NCT05703685

Depression

RECRUITING PHASE1

The Effects of Sleep Deprivation on Antidepressant Response

NCT00178074

Unipolar Depression

COMPLETED PHASE4

Using Neuroimaging to Investigate Major Depressive Disorder

NCT00781677

Major Depressive Disorder Depression Anxiety

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Depression is a common psychological disorder caused by various factors, characterized by significant and persistent low mood, loss of interest, and anhedonia as core symptoms, leading to physical, psychological, and social dysfunctions, with a high risk of suicide. The pathogenesis of depression remains a challenging topic in the medical field. Imaging studies are crucial for exploring the pathogenesis of depression. Recently, neuroinflammation has gained significant attention regarding the pathophysiological mechanisms of depression. Neuroinflammation, a chronic inflammatory response of the immune system in the central nervous system, may be related to the onset and progression of depression. PET is an imaging method that uses radioactive tracers to visualize physiological activities and metabolic processes in the body. 18F-FDG-PET can reflect neuronal degeneration and the reduction in the number and function of protrusions in vitro, directly indicating lesion sites and involvement. Therefore, PET/MRI brain metabolism imaging can uncover possible pathogenesis and explore unique brain network characteristics from a molecular imaging perspective. PET studies can depict local functional metabolism and neurochemical changes in the brain through radionuclide labeling. \[18F\]DPA-714, a PET tracer, is a high-affinity ligand for the translocator protein (TSPO), a mitochondrial outer membrane protein expressed in activated microglia and macrophages in the brain, serving as a marker of neuroinflammation. As a TSPO radioligand, DPA-714 can explore in vivo changes in neuroinflammation. Combining these two tracers can explore the correlation between neuroinflammation and glucose metabolism in depression, further elucidating its possible mechanisms.

This study will collect data from patients diagnosed with recurrent depression and first-episode depression in the Psychosomatic Sleep Department and Neurology Department of the First Affiliated Hospital of Dalian Medical University. Healthy individuals who underwent "DPA-714 or FDG imaging PET/MRI" physical examinations in the PET/CT room of our hospital will also be included. According to the inclusion and exclusion criteria, the groups will consist of 25 cases of recurrent depression, 25 cases of first-episode depression, and 20 healthy controls. Additionally, all three groups will undergo neuropsychological assessments, including Hamilton Anxiety Scale, Hamilton Depression Scale, Mini-mental State Examination, Montreal Cognitive Assessment, Pittsburgh Sleep Quality Index Scale, and other related cognitive, sleep, and emotional scales. We used DPA-714 imaging agent PET/MRI to scan the whole brain, selecting major gray matter regions of interest (prefrontal cortex, anterior cingulate cortex, and insula) and 12 additional regions and subregions to measure TSPO values. The patients with recurrent depression and first episode depression were compared with the normal control group to explore their characteristics. Moreover, through the relationship between TSPO values and neuropsychological scores, the correlation between TSPO values and depression severity was explored.

The statistical method we use is that SPSS26.0 statistical software (IBM, New York, United States) was used to conduct statistical analysis on the basic demographic data of each group. Normal test and homogeneity test of variance were performed on the data. Continuous variables conforming to normal distribution were expressed in the form of mean ± standard deviation (±s). Samples that do not conform to a normal distribution and variables represented as graded data are described by the median (interquartile range). The Chi-square test was used to compare categorical data groups. For normally distributed data, a two independent sample T-test was employed. Non-normally distributed data were analyzed using the Mann-Whitney U test. Pearson or Spearman correlation coefficients were used for correlation analysis, depending on the data distribution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recurrent depression patients group

Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in patients with recurrent depression.

Group Type EXPERIMENTAL

PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG

Intervention Type RADIATION

Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

First-episode depression patients group

Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in patients with first episode depression.

Group Type EXPERIMENTAL

PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG

Intervention Type RADIATION

Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Healthy controls group

Evaluation of neuroinflammation and cerebral metabolism in the prefrontal cortex, anterior cingulate cortex, insula, and other brain regions of interest in healthy controls.

Group Type OTHER

PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG

Intervention Type RADIATION

Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET scan with tracer injection [18F] DPA-714 or [18F]F-FDG

Brain PET/MRI imaging will be conducted following the administration of \[18F\] DPA-714 or \[18F\]F-FDG. The radiopharmaceuticals are given intravenously in doses that are safe for the human body, with minimal quantities to reduce potential effects. Additionally, the irradiation levels are kept low, ensuring the procedure is safe and reliable for patients.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For all groups :

* No alcohol or psychoactive substances such as coffee had been consumed in the 24 hours prior to the examination
* MMSE≥24 points，MOCA≥26 points
* No anti-infective drugs in the past 1 month, no cold, fever or other infection history in the past 2 weeks
* Patients with diabetes had fasting controlled below 9.0mmol/L before the examination
* Volunteer to participate in the study and sign the informed consent
2. For Recurrent depression patients:

* Meet the Diagnostic criteria for recurrent major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)
* Age 35-85 years old, gender is not limited
* HAMD≥8 points
3. For first episode depression Patients:

* Gender, age and education level were matched with the recurrent depression group
* Meet the Diagnostic criteria for the first episode of depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)
* HAMD≥8 points
4. For controls:

* Healthy people undergoing "DPA-714 or FDG imaging PET/MRI" physical examination in PET/CT room of our hospital
* Gender and education level were consistent with both the recurrent depression group and the first-episode depression group
* never used any psychotropic drugs
* HAMD\<8 points；HAMA\<7 points

Exclusion Criteria

* Have a history of organic mental disorders or other mental disorders
* A family history of hereditary diseases
* Persons with mental retardation or dementia
* A history of psychoactive substance abuse
* Can not cooperate with/complete the psychological examination scale
* Previously found serious physical diseases (heart, brain, liver, lung and kidney)
* MRI contraindications, abnormalities found in head CT or MRI
* A history of drug or alcohol abuse
* Have a history of metabolic diseases such as hyperthyroidism, hypothyroidism,and rheumatic diseases
* are in the state of pregnancy or breastfeeding

Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes